Esperion Therapeutics AI Price Prediction

The negative EPS of -6.24 and a PE ratio of -0.51 indicate that Esperion Therapeutics remains loss‑making, with no current earnings support for the stock. The valuation is therefore driven more by expectations of future turnaround or pipeline success than by present profitability. Without evidence of improving margins or a clear path to positive earnings, the financial profile is fundamentally weak.

• Negative EPS (-6.24) and a negative PE ratio (-0.51) confirm that the company is not currently profitable, signaling ongoing operating or R&D losses.
• The lack of positive earnings means the stock’s valuation is based largely on future growth and clinical/commercial execution rather than current cash flows.
• Until there is a clear trend toward improving earnings or profitability ratios, the financial backdrop remains a headwind for long‑term, fundamentals‑driven investors.

Alternative data for Esperion Therapeutics points to weakening operational and engagement trends. Job openings have dropped sharply (9 roles, down 69% month over month), which can signal cost‑cutting or a slowdown in planned expansion. Social media metrics are flat to slightly negative on Twitter/X and only stable on LinkedIn, and modest web traffic levels do not suggest surging commercial or investor interest.

• Job postings at 9, down 69% month over month, indicate a significant hiring pullback that may reflect budget constraints, restructuring, or reduced growth initiatives.
• Twitter/X followers at 2,110 have declined by 0.6% over the last 90 days, suggesting waning retail or public engagement, while LinkedIn followers (24,177) appear stable but not rapidly expanding.
• Estimated monthly web traffic of 16,050 visitors is relatively modest and does not point to a strong upswing in customer, physician, or investor interest at this time.